Sign In
Buy ERAS
$13.67
-0.310 (-2.22%)
At Close: Jun 18, 2026
4 Penny Stocks To Watch Before Next Week With Big News
10:07am, Friday, 08'th Dec 2023
Penny stocks, defined as stocks trading under $5 per share, are known for their volatility. Even small pieces of news or unconfirmed rumors can send some penny stocks swinging wildly up or down in pri
3 Penny Stocks To Buy According To Insiders In December
03:36pm, Thursday, 07'th Dec 2023
Penny stocks – the cheap stocks trading under $5 per share, offer investors massive upside potential alongside higher risk. Since even incremental price moves translate into huge percentage gains in
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
08:00am, Tuesday, 28'th Nov 2023
Gained alignment with global health authorities for pivotal Phase 3 SEACRAFT-2 trial design for naporafenib plus trametinib in NRAS mutant melanoma; initiation on track for H1 2024
Erasca Reports Third Quarter 2023 Financial Results and Business Updates
04:01pm, Thursday, 09'th Nov 2023
First patient dosed in SEACRAFT-1 Phase 1b trial evaluating naporafenib plus trametinib Multiple upcoming catalysts across ongoing clinical programs Strong balance sheet with cash, cash equivalents, a
Erasca to Present at Upcoming Investor Conferences in November
08:00am, Wednesday, 08'th Nov 2023
SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
Why Shares of Erasca Are Jumping Tuesday
03:56pm, Tuesday, 10'th Oct 2023
Erasca is a clinical-stage biotech that focuses on oncology treatments. The company has a deep pipeline with 12 programs.
Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
08:00am, Tuesday, 05'th Sep 2023
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for
August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge
06:05am, Monday, 28'th Aug 2023
Two new sample Breakout Stocks for Week 35 curated by the MDA model for a 10% short-term upside along with a Dow pick. The Momentum Gauges, S&P 500 Gauges, and Weekly Gauges all continue negative afte
August MDA Breakout Stocks Week 33 - 2023: Facing The Largest Negative Signal Since February
03:22pm, Monday, 14'th Aug 2023
Two new Breakout Stocks for Week 33 curated by the MDA model for 10% short-term upside along with one Dow pick. Last week two of four picks gained over the 10% mark in less than a week with peak gains
Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting
05:00pm, Thursday, 25'th May 2023
Triplet of ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with metastatic BRAF V600E-mutated colorectal cancer (CRC) showed a 40% (2/5) response rate; continued evaluation
Goldman Sachs Maintains Erasca Buy Recommendation
10:34pm, Tuesday, 16'th May 2023
Fintel reports that on May 16, 2023, Goldman Sachs maintained coverage of Erasca (NASDAQ:ERAS) with a Buy recommendation.
Erasca: Potential Strong Upside Ahead
11:21am, Wednesday, 08'th Feb 2023
Erasca, Inc. is a clinical-stage biopharmaceutical developer of therapies for patients with RAS/MAPK pathway-driven cancers. Shares were dragged down sharply by headwinds from the Fed's hawkish stance
MDA Breakout Stocks Week 6 - February 2023: High-Frequency Gainers To Give You An Edge
08:01am, Monday, 06'th Feb 2023
Two new Breakout Stocks for Week 6 with better than 10% short-term upside and two Dow 30 Picks. Average cumulative returns for 2023 are +28.2% YTD. This week 3 of 4 high-frequency breakout picks gaine
Erasca to Present at the Guggenheim Oncology Conference 2023
08:00am, Wednesday, 01'st Feb 2023
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 04'th Jan 2023
SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
